Dermatol. praxi. 2023;17(4):193-197 [Klin Farmakol Farm. 2023;37(3):115-118]

Topical treatment of basal cell carcinoma - current state and future perspectives

MUDr. Paula Ďuríková
Dermatovenerologická klinika Lekárskej fakulty Univerzity Komenského a Univerzitnej nemocnice Bratislava

Basal cell carcinoma is one of the most common malignancies worldwide. In the indication of topical treatment of basal cell carcinoma, imiquimod and photodynamic therapy play a central role. These modalities are reserved for low-risk superficial subtypes, which reduces their degree of applicability in clinical practice. With the intention of overcoming current limitations, extensive research is conducted in the field of topical treatment of basal cell carcinoma. This article briefly summarizes the current therapeutic modalities, their limitations, and examples of new approaches in the treatment of this highly prevalent disease.

Keywords: basal cell carcinoma, imiquimod, nanoparticles, patidegib, vismodegib.

Published: November 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuríková P. Topical treatment of basal cell carcinoma - current state and future perspectives. Dermatol. praxi. 2023;17(4):193-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma. Journal of the American Academy of Dermatology. 2019;80(2):303-317. Go to original source... Go to PubMed...
    2. Seidl-Philipp M, Frischhut N, Höllweger N, et al. Known and new facts on basal cell carcinoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2021;19(7):1021-1041. Go to original source... Go to PubMed...
    3. Kilinc AN. Early-onset basal cell carcinoma; wide case series at a single tertiary center in Middle Anatolia. Northern Clinics of Istanbul. 2022;9(3):261-265. Go to original source... Go to PubMed...
    4. Stundys D, Ulianskaite G, Stundiene I, et al. The quality of life in surgically treated head and neck basal cell carcinoma patients: A comprehensive review. Cancers. 2023;15(3):801. Go to original source... Go to PubMed...
    5. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 2018;78(3):540-559. Go to original source... Go to PubMed...
    6. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology. 2004;50(5):722-733. Go to original source... Go to PubMed...
    7. Roldán-Marín R, Toussaint-Caire S. Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response. Dermatology and Therapy. 2015;5(4):265-272. Go to original source... Go to PubMed...
    8. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of SBCC. British Journal of Dermatology. 2013;169(3):549-554. Go to original source... Go to PubMed...
    9. Roozeboom MH, Arits AHHM, Nelemans PJ, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. British Journal of Dermatology. 2012;167(4):733-756. Go to original source... Go to PubMed...
    10. Sharquie KE, Noaimi AA. Basal cell carcinoma: topical therapy versus surgical treatment. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2012;16(2):41-51. Go to original source...
    11. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 2018;78(3):540-559. Go to original source... Go to PubMed...
    12. van Delft LCJ, Nelemans PJ, Kessels JPHM, et al. Long-term efficacy of photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus conventional two-stage topical methyl aminolevulinate for superficial basal-cell carcinoma. Dermatology. 2022;238(6):1044-1049. Go to original source... Go to PubMed...
    13. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. International Journal of Dermatology. 2006;45(5):489-498. Go to original source... Go to PubMed...
    14. Habashy S, Jafri A, Osman HO, et al. Hedgehog pathway inhibitors: Clinical implications and resistance in the treatment of basal cell carcinoma. Cureus. 2021;13(3):13859. Go to original source... Go to PubMed...
    15. Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. International Journal of Molecular Sciences. 2022;23(3):1733. Go to original source... Go to PubMed...
    16. Gambini D, Passoni E, Nazzaro G, et al. Basal cell carcinoma and hedgehog pathway inhibitors: Focus on immune response. Frontiers in Medicine. 2022;9. Go to original source... Go to PubMed...
    17. Yin VT, Sniegowski M, Esmaeli B. Indications and limitations of vismodegib for basal cell carcinoma. JAMA Ophthalmology. 2014;132(7):905-906. Go to original source... Go to PubMed...
    18. Cozzani R, Aguila R, Carrizo M, et al. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. International Journal of Dermatology. 2020;59(5):627-632. Go to original source... Go to PubMed...
    19. ClinicalTrials.gov. Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin SynDrome Patients - Full Text View. [cited 2023 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02762084.
    20. ClinicalTrials.gov. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas - Full Text View. [cited 2023 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02828111.
    21. Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Advances in Therapy. 2022;39(3):1164-1178. Go to original source... Go to PubMed...
    22. Verkouteren BJA, Sinx KAE, Reinders MGHC, et al. Update on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma. Acta Dermato-Venereologica. 2022;102:980. Go to original source... Go to PubMed...
    23. Zeng L, Gowda BH, Ahmed MG, et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Molecular Cancer. 2023;22(1). Go to original source... Go to PubMed...
    24. Souto EB, Macedo AS, Dias-Ferreira J, et al. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (apis). International Journal of Molecular Sciences. 2021;22(18):9743. Go to original source... Go to PubMed...
    25. Zielińska A, Szalata M, Gorczyński A, et al. Cancer nanopharmaceuticals: Physicochemical characterization and in vitro/in vivo applications. Cancers. 2021;13(8):1896. Go to original source... Go to PubMed...
    26. Calienni MN, Febres-Molina C, Llovera RE, et al. Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment. International Journal of Pharmaceutics. 2019;565:108-122. Go to original source... Go to PubMed...
    27. Morton CA, Dominicus R, Radny P, et al. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. British Journal of Dermatology. 2018;179(2):309-319. Go to original source... Go to PubMed...
    28. Mohammadpour R, Dobrovolskaia MA, Cheney DL, et al. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for Delivery Applications. Advanced Drug Delivery Reviews. 2019;144:112-132. Go to original source... Go to PubMed...
    29. Tang W, Fan W, Lau J, et al. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chemical Society Reviews. 2019;48(11):2967-3014. Go to original source... Go to PubMed...
    30. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of SBCC. British Journal of Dermatology. 2013;169(3):549-554. Go to original source... Go to PubMed...
    31. Łasińska I, Zielińska A, Mackiewicz J, et al. Basal cell carcinoma: Pathology, current clinical treatment, and potential use of lipid nanoparticles. Cancers. 2022;14(11):2778. Go to original source... Go to PubMed...
    32. Dourmishev LA, Rusinova D, Botev I. Clinical variants, sta­ges, and management of basal cell carcinoma. Indian Dermatology Online Journal. 2013;4(1):12. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.